Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1982 Aug;49(2):467–473.

Defects of serum chemoattraction and polymorphonuclear leucocyte movement in patients with primary hepatocellular carcinoma.

A G Yousif-Kadaru, R J Wyke, I A Rajkovic, A L Eddleston, R Williams
PMCID: PMC1536499  PMID: 6290116

Abstract

Movement of polymorphonuclear leucocytes to the site of tumour cells may be an important stage in host defences against tumours in a variety of organs. In this study, sera from 29 of 30 patients with primary hepatocellular carcinoma had reduced ability to stimulate the movement in vitro of normal polymorphonuclear leucocytes. The serum defect was more severe in 11 patients with underlying cirrhosis but was not related to abnormalities of tests of liver function, levels of serum alphafetoprotein, or deficiency of complement factors C3 and C5. Serial studies showed that the defect was persistent and progressive in patients in whom the tumour did not respond to treatment. In 35% of patients, mainly those with cirrhosis, the sera contained antagonists to normal serum chemotactic factors which were heat stable and dialysable, but could be distinguished by their effect on complement factor C5a. A heat labile dialysable antagonist(s) was found in sera from 28% of the patients (mainly those without cirrhosis) which antagonized the movement of normal polymorphonuclear leucocytes (cell directed antagonism). In addition to these serum defects, polymorphonuclear leucocytes from two of seven patients studied had reduced movement which was not related to the presence in the serum of cell directed antagonists. These serum and cellular defects have not been reported previously in patients with primary hepatocellular carcinoma, and could compromise the body's defences against the tumour.

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggett P. J., Harries J. T., Harvey B. A., Soothill J. F. An inherited defect of neutrophil mobility in Shwachman syndrome. J Pediatr. 1979 Mar;94(3):391–394. doi: 10.1016/s0022-3476(79)80578-8. [DOI] [PubMed] [Google Scholar]
  2. Anderson R., Theron A. Effects of ascorbate on leucocytes: Part I. Effects of ascorbate on neutrophil motility and intracellular cyclic nucleotide levels in vitro. S Afr Med J. 1979 Sep 1;56(10):394–400. [PubMed] [Google Scholar]
  3. BERG J. W. Inflammation and prognosis in breast cancer; a search for host resistance. Cancer. 1959 Jul-Aug;12(4):714–720. doi: 10.1002/1097-0142(195907/08)12:4<714::aid-cncr2820120414>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. Beebe D. P., Ward P. A., Spitznagel J. K. Isolation and characterization of an acidic chemotactic factor from complement-activated human serum. Clin Immunol Immunopathol. 1980 Jan;15(1):88–105. doi: 10.1016/0090-1229(80)90023-9. [DOI] [PubMed] [Google Scholar]
  5. Brozna J. P., Ward P. A. Antileukotactic properties of tumor cells. J Clin Invest. 1975 Sep;56(3):616–623. doi: 10.1172/JCI108131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dvorak A. M., Connell A. B., Proppe K., Dvorak H. F. Immunologic rejection of mammary adenocarcinoma (TA3-St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation. J Immunol. 1978 Apr;120(4):1240–1248. [PubMed] [Google Scholar]
  7. Gallin J. I., Sandler J. A., Clyman R. I., Manganiello V. C., Vaughan M. Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol. 1978 Feb;120(2):492–496. [PubMed] [Google Scholar]
  8. Gupta S., Good R. A. Alpha-fetoprotein and human lymphocyte subpopulations. J Immunol. 1977 Feb;118(2):405–408. [PubMed] [Google Scholar]
  9. Halbrecht I., Komlos L. Cytotoxic effects of leukocytes and plasma on primary cultures of ovarian carcinoma. Obstet Gynecol. 1974 Feb;43(2):268–275. [PubMed] [Google Scholar]
  10. Maderazo E. G., Anton T. F., Ward P. A. Serum-associated inhibition of leukotaxis in humans with cancer. Clin Immunol Immunopathol. 1978 Feb;9(2):166–176. doi: 10.1016/0090-1229(78)90068-5. [DOI] [PubMed] [Google Scholar]
  11. Sandler J. A., Gallin J. I., Vaughan M. Effects of serotonin, carbamylcholine, and ascorbic acid on leukocyte cyclic GMP and chemotaxis. J Cell Biol. 1975 Nov;67(2PT1):480–484. doi: 10.1083/jcb.67.2.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Van Epps D. E., Strickland R. G., Williams R. C., Jr Inhibitors of leukocyte chemotaxis in alcoholic liver disease. Am J Med. 1975 Aug;59(2):200–207. doi: 10.1016/0002-9343(75)90354-x. [DOI] [PubMed] [Google Scholar]
  13. Vierucci A., London W. T., De Martino M., Blumberg B. S. Neutrophil function in children who are carriers of hepatitis-B surface antigen. Lancet. 1977 Jan 22;1(8004):157–160. doi: 10.1016/s0140-6736(77)91761-5. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES